A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)

NCT04379271 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

234

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: IMU-838
OTHER: Placebo

Sponsor

Immunic AG

Collaborators

[object Object]